TY - JOUR
T1 - Occult primary, version 3.2014; Featured updates to the NCCN guidelines
AU - Ettinger, David S.
AU - Handorf, Charles R.
AU - Agulnik, Mark
AU - Bowles, Daniel W.
AU - Cates, Justin M.
AU - Cristea, Mihaela
AU - Dotan, Efrat
AU - Eaton, Keith D.
AU - Fidias, Panagiotis M.
AU - Gierada, David
AU - Weldon Gilcrease, G.
AU - Godby, Kelly
AU - Iyer, Renuka
AU - Lenzi, Renato
AU - Phay, John
AU - Rashid, Asif
AU - Saltz, Leonard
AU - Schwab, Richard B.
AU - Shulman, Lawrence N.
AU - Smerage, Jeffrey B.
AU - Stevenson, Marvaretta M.
AU - Varadhachary, Gauri R.
AU - Zager, Jonathan S.
AU - Zhen, Weining
AU - Bergman, Mary Anne
AU - Freedman-Cass, Deborah A.
PY - 2014/7/1
Y1 - 2014/7/1
N2 - The NCCN Guidelines for Occult Primary tumors provide recommendations for the evaluation, workup, management, and follow-up of patients with occult primary tumors (cancers of unknown primary). These NCCN Guidelines Insights summarize major discussion points of the 2014 NCCN Occult Primary panel meeting. The panel discussed gene expression profiling (GEP) for the identification of the tissue of origin and concluded that, although GEP has a diagnostic benefit, a clinical benefit has not been demonstrated. The panel recommends against GEP as standard management, although 20% of the panel believes the diagnostic benefit of GEP warrants its routine use. In addition, the panel discussed testing for actionable mutations (eg, ALK) to help guide choice of therapy, but declined to add this recommendation.
AB - The NCCN Guidelines for Occult Primary tumors provide recommendations for the evaluation, workup, management, and follow-up of patients with occult primary tumors (cancers of unknown primary). These NCCN Guidelines Insights summarize major discussion points of the 2014 NCCN Occult Primary panel meeting. The panel discussed gene expression profiling (GEP) for the identification of the tissue of origin and concluded that, although GEP has a diagnostic benefit, a clinical benefit has not been demonstrated. The panel recommends against GEP as standard management, although 20% of the panel believes the diagnostic benefit of GEP warrants its routine use. In addition, the panel discussed testing for actionable mutations (eg, ALK) to help guide choice of therapy, but declined to add this recommendation.
UR - http://www.scopus.com/inward/record.url?scp=84903965503&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84903965503&partnerID=8YFLogxK
U2 - 10.6004/jnccn.2014.0093
DO - 10.6004/jnccn.2014.0093
M3 - Article
C2 - 24994917
AN - SCOPUS:84903965503
SN - 1540-1405
VL - 12
SP - 969
EP - 974
JO - JNCCN Journal of the National Comprehensive Cancer Network
JF - JNCCN Journal of the National Comprehensive Cancer Network
IS - 7
ER -